Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual MeetingZhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting Zhejiang Wenda Pharmaceutical Technology Co., Ltd. Oct 24, 2026, 21:00 ETSHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the ph ...